JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $3.87.
Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Madrigal Pharmaceuticals. According to TipRanks, Wolleben has an average return of 10.3% and a 41.62% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $11.25 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $6.53 and a one-year low of $2.57. Currently, Ocular Therapeutix has an average volume of 637.4K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCUL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Read More on OCUL:
- Ocular Therapeutix price target lowered to $12 from $25 at JMP Securities
- Ocular Therapeutix provides 2022 update, reviews 2023 milestones
- Ocular Therapeutix sees cash runway through middle of 2024
- Ocular Therapeutix sees Q4 product revenue $13.6M
- Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
